Read More

Candel Therapeutics Announces Restructuring To Prioritize Resources On Key Value Drivers For Expanded Development Of CAN-3110, The enLIGHTEN Discovery Platform, And Key Clinical Readouts For CAN-2409; Decreases Workforce By ~50%

Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and

CADL